Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced full year 2023 financial results, and provided clinical development and business updates.